Clinical Trial

Pneumococcal Community-Acquired Pneumonia Requiring Hospitalization Among Colombian Adults

Study acronym: PneumoCAP
Completed
View on ClinicalTrials.gov →
Summary
Pneumococcal Community-Acquired Pneumonia Requiring Hospitalization Among Adults in Colombia (Pneumo-CAP Colombia) This study aims to learn more about pneumococcal community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae among adults hospitalized in 11 hospitals in the Sabana Centro region of Colombia. The study will describe the characteristics of adults with CAP, estimate pneumococcal CAP prevalence in the area, and examine the specific serotypes of S. pneumoniae causing this infection. This research is essential for understanding which microorganism is the most prevalent cause of CAP in the region, whether pneumococcal vaccines included in governmental vaccination programs protect adults, which specific pneumococcal serotypes are circulating, and which available vaccine will best protect people against pneumococcal CAP. The study will be conducted at 11 hospitals in the Sabana Centro region and will collect data over 2 years. The study will gather detailed information on each patient's condition, including symptoms, medical history, and outcomes such as death or the need for intensive care.
Trial Details
NCT Number NCT07354425
Lead Sponsor Universidad de la Sabana
Collaborators: Clínica Universidad de La Sabana, Universidad de La Sabana, Colombia
Conditions Community Acquired Pneumonia (CAP), Pneumococcal Pneumonia
Enrollment 688 participants
Start Date 2022-06-28
Primary Completion 2025-02-25 (estimated)
Study Completion 2025-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-01-21